BYJHD can down-regulate the phosphorylation of Smad protein by inhibiting the expression of tumour ACVRL1, and reduce the expression of the target gene ID-1 and the surface marker CD34 in the tumour microenvironment to regulate tumour angiogenesis, leading to anti-NSCLC effects. Here, CD34 is linked to non-small cell lung carcinoma.